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Abstract
Epstein-Barr virus (EBV), an oncogenic human herpesvirus, induces cell proliferation after infection of resting B lymphocytes,
its reservoir in vivo. The viral latent proteins are necessary for permanent B cell growth, but it is unknown whether they are
sufficient. EBV was recently found to encode microRNAs (miRNAs) that are expressed in infected B cells and in some EBV-
associated lymphomas. EBV miRNAs are grouped into two clusters located either adjacent to the BHRF1 gene or in introns
contained within the viral BART transcripts. To understand the role of the BHRF1 miRNA cluster, we have constructed a virus
mutant that lacks all its three members (D123) and a revertant virus. Here we show that the B cell transforming capacity of
the D123 EBV mutant is reduced by more than 20-fold, relative to wild type or revertant viruses. B cells exposed to the
knock-out virus displayed slower growth, and exhibited a two-fold reduction in the percentage of cells entering the cell
cycle S phase. Furthermore, they displayed higher latent gene expression levels and latent protein production than their
wild type counterparts. Therefore, the BHRF1 miRNAs accelerate B cell expansion at lower latent gene expression levels.
Thus, this miRNA cluster simultaneously enhances expansion of the virus reservoir and reduces the viral antigenic load, two
features that have the potential to facilitate persistence of the virus in the infected host. Thus, the EBV BHRF1 miRNAs may
represent new therapeutic targets for the treatment of some EBV-associated lymphomas.
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Introduction
Epstein-Barr virus (EBV) establishes a clinically silent chronic
infection in the large majority of the world population [1]. In the
course of primary infection, B cells targeted by the virus initiate
transient cell growth until EBV-specific CD8+ T cells mount an
efficient antiviral response [2]. However, some EBV-infected B cells
will persist in the infected individual and form a long-lasting virus
reservoir. In transplant recipients undergoing immunosuppressive
therapy, EBV-induced B cell growth can lead to the development of
a post-transplant lymphoproliferative disorder (PTLD) [1], and
analogous conditions have been observed in other immunodeficient
patients. This process can be reproduced in vitro; exposure of resting
B cells to the virus leads to the generation of continuously growing
lymphoblastoid cell lines (LCL). Both typical PTLD cells and LCLs
produce all six Epstein-Barr virus nuclear antigens (EBNA) and
three latent membrane proteins (LMP), collectively designated
latent proteins [1]. Viral mutants that lack EBNA1, EBNA2,
EBNA-LP or LMP1 display a massive reduction in their ability to
transform B cells [3–7], thereby demonstrating that latent proteins
are necessary for this process. However, it remains unclear whether
they are sufficient for Bcell transformation.
The EBV genome encodes a large number of non-coding RNAs
that include the Epstein-Barr encoded RNAs (EBERs), as well as
25 miRNAs and one small nucleolar RNA (snoRNA) [8–12].
MiRNAs bind to mRNAs that contain fully or partially
complementary sequences and as a consequence usually impair
their translation and reduce their stability [13]. The EBV miRNAs
are distributed in two clusters, located in the BART region or
within the BHRF1 gene locus [9,10]. The latter cluster comprises
three members, two of which are located in the BHRF1 39
untranslated region and the third immediately 59 to the BHRF1
lytic mRNA transcription start site [9,10] (Fig. 1A). They are
processed from introns located within ,100-kb long RNA
transcripts that initiate at the Cp or Wp promoters used by all
EBNA genes [14]. Expression of the BHRF1 miRNAs is
characteristic of EBV-transformed B cells that express all latent
genes (latency III) [1,10]. In contrast, Bcell tumours such as
Burkitt’s lymphomas or epithelial cell tumours that express a
restricted number of latent proteins (latency I or II) do not express
the BHRF1 miRNAs [10]. However, induction of virus replication
in some Burkitt’s lymphoma cells leads to re-expression of the
miRNA BHRF1 cluster, suggesting that these miRNAs may serve
functions not only during latency III but also upon induction of
virus replication [15]. In an attempt to understand the function of
the BHRF1 miRNA cluster in continuously growing lymphoblas-
toid B cell lines, we constructed viruses that lack these miRNAs
and report here their phenotypic traits.
PLoS Pathogens | www.plospathogens.org 1 February 2011 | Volume 7 | Issue 2 | e1001294Results
Construction of viral mutants
We deleted the BHRF1 miRNA cluster from the B95.8 genome
cloned in E.coli in a sequential manner (Fig. 1). We first exchanged
the miR-BHRF1-1 seed region for an unrelated sequence by
chromosomal building using a shuttle plasmid that carries an
ampicillin resistance cassette [16]. The modified miR-BHRF1-1
seed region introduces an AclI restriction site that allows
unequivocal identification of the properly recombined mutant.
In a second step, we replaced the DNA region that spans the miR-
BHRF1-2 and miR-BHRF1-3 mature miRNAs by a kanamycin
resistance cassette flanked by Flp recombinase target sites using
recA-mediated homologous recombination. The last step consisted
in excising the kanamycin resistance cassette by transient
expression of the Flp recombinase. As a result, the miR-BHRF1-
2 and miR-BHRF1-3 miRNAs were exchanged against one Flp
recombinase target site (Fig. 1 and Fig. S1). The modified viral
DNA, which carries a hygromycin resistance cassette, hereinafter
referred to as D123, was then transfected into 293 cells. Clones
from these stably transfected 293 cells (293/D123) were obtained
by hygromycin selection and the viral mutant genomes present in
these producing cell lines were transferred back into E.coli and
their global integrity was confirmed by restriction enzyme analysis
(Fig. 2A). Furthermore, sequencing the DNA fragments that were
modified during virus construction confirmed the exactitude of the
introduced alterations (Fig. S2) and the complete identity of
sequences outside the miRNAs with wild type genome. Next, the
producer cell clones were tested for their ability to sustain viral
lytic replication. The viral structural titers were detected by
quantitative PCR and found to be similar to those observed with
wild type producer cell lines. The mean values ranged between
2.2610
7 and 2.9610
7 genome equivalents per ml of supernatant
for D123 and wt, respectively, showing that the BHRF1 miRNAs
are not required for virus production (Fig. 2B). We then incubated
Raji B cells with these supernatants at various dilutions. Three
days later the number of gfp-positive Raji cells was determined to
assess functional infectious titers (Fig. 2B). The ratio between
structural titers (geq/ml) and functional titers (gru/ml) was found
to be 7.8 and 10.3 for wt and D123 viruses, respectively. We
therefore conclude, that the BHRF1 miRNAs are not essential for
EBV infection but we cannot rule out a minor contribution to this
process.
The genome with the triple miRNA mutation formed the basis
for construction of a revertant virus in which the modified
sequences were re-exchanged with the original ones by chromo-
somal building to generate a D123 revertant (D123 Rev) virus
genome [16]. This technique allows exact reconstruction of the
original wild type sequence. The reverted genome was introduced
in turn into 293 cells from which hygromycin-resistant clones were
selected. Restriction analysis and sequencing confirmed that the
revertant virus shared perfect homology with the wild type EBV
genome (Fig. 2A and Fig. S2). Producer clones carrying the
Figure 1. Construction of the BHRF1 miRNA viral mutant. Schematic representing part of the EBV wild type genome with a focus on the
BHRF1 miRNA cluster (top panel; not to scale). The two promoters for latent EBNA transcripts (Cp, Wp) and the polyA site of the BHRF1 gene are
indicated. Construction of the D123 mutant was performed in three sequential steps (lower panel). First, the seed region of miR-BHRF1-1 was
mutated using chromosomal building. The seed region is indicated in red and introduced sequence changes are shown in blue. This also created a
new AclI restriction enzyme site (underlined). Second, the mature miR-BHRF1-2 and miR-BHRF1-3 sequences were replaced by a kanamycin resistance
cassette flanked by flip recombinase target (frt) sites. Third, transient expression of the flp recombinase led to the excision of the kanamycin cassette.
doi:10.1371/journal.ppat.1001294.g001
Author Summary
To persist in their hosts, herpes viruses must avoid
recognition by the host’s immune system. Down-regula-
tion of viral antigen production through expression of viral
miRNAs is a particularly elegant mechanism as these
genetic elements do not encode proteins and remain
therefore invisible to the immune system. Upon primary
infection, Epstein-Barr virus (EBV) colonizes B cells and,
through expression of its latent proteins, induces their
continuous proliferation. The resulting expansion of
infected B cells elicits a T cell response directed against
the latent proteins that results in their elimination.
Therefore, rapid proliferation of infected B cells, combined
with reduced latent protein production, would facilitate
establishment of EBV’s viral reservoir before mounting of
the immune response. Here, we find that a cluster of three
microRNAs encoded near the EBV BHRF1 gene is crucial for
efficient B cell transformation. In the absence of these
genetic elements, infected B cells grow markedly more
slowly. Furthermore, B cells exposed to an EBV mutant that
lacks the BHRF1 microRNA cluster produced more latent
proteins. Thus, the BHRF1 microRNA cluster possesses
properties that potentiate EBV’s oncogenic properties and
therefore facilitate expansion of the EBV B cell reservoir.
EBV microRNAs and B Cell Transformation
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those observed with wt viruses (Fig. 2B).
A virus that lacks the BHRF1 miRNA cluster displays
reduced transformation capacity
To assess the contribution of the BHRF1 miRNA cluster to
EBV’s transforming properties, we exposed resting primary B cells
to wild type, D123, and D123 Rev viruses. Infections were carried
out at an MOI of 1 infectious particle per B cell (i.e. one gru/B
cell), and cell outgrowth was monitored. Infected B cells were
either seeded at low concentration, i.e. 2610
3 per ml in a 96-well
plate containing feeder cells or at high concentration i.e. 2610
6
cells per ml. EBV-infected cells grow much more easily when
infected at high concentration. Therefore, the first culture
conditions are very stringent and allow detection of differences
in terms of transformation efficiency but they do not allow
monitoring of the infected B cells at the early stages of
transformation. The percentage of wells containing outgrowing
cell clones was assessed 8 weeks after infection. The results of three
independent infection experiments is presented in Figure 3A. On
average, wild type and revertant viruses respectively induced 82
and 75% cell outgrowth at an MOI of 1. In contrast, only 3% of
the wells containing B cells infected with D123 virus showed
outgrowth (Fig. 3A). Note that the standard variation between the
different transformation assays was high. This reflects the fact that
B cells from different individuals differ in their ability to form
continuously growing cell lines. We conclude from these data that
the BHRF1 miRNA cluster markedly increases the efficiency of
transformation at low B cell concentration. The results of the bulk
infection revealed similar though less pronounced effects. Moni-
toring of cell growth in B cells exposed to EBV-wt, D123, and
D123 Rev virus evidenced slower growth in samples infected with
D123. After 29 days in culture, B cells exposed to wild type or
D123 Rev viruses expanded from 2610
6 to 3.6610
8 and 3.3610
8
cells, respectively. This compares with 1.3610
8 for B cells
transformed by D123 (Fig. 3B). This prompted us to study the
cell cycle parameters of B cell populations, by performing a BrdU
incorporation assay (Fig. 3C). Whilst between 22 and 23% of B
cells infected with both wild type controls entered S phase within
30 minutes, this percentage fell to 9.4% in B cells infected with
D123 virus. We also noted that the ratio between cells still present
in G2/M phase at the time of analysis and those that had entered
S phase was ,0.3 for the controls and ,0.9 for B cells infected
D123 virus. From this set of data, we conclude that the absence of
BHRF1 miRNAs does not suppress EBV’s transforming proper-
ties, but instead markedly slows down the growth rate of infected
target cells. The permanently growing cell lines obtained after
D123 infection provided material to quantify BHRF1 miRNA
expression by RT-qPCR using the RNU48 snoRNA as an internal
reference. The results of this analysis are given in Fig. 3D and
show expression of the three BHRF1 miRNAs in all control lines
tested, but not in those generated with D123, as expected. Of note,
the expression level of the BHRF1 miRNAs varies within the
control LCLs established from three different B cell infections (1 to
5 range for miR-BHRF1-1, 1 to 4 range for miR-BHRF1-2, 1 to 2
range for miR-BHRF1-3). This variation most likely reflects
different activity levels of the Cp/Wp promoter among different
LCLs [15].
Figure 2. Characterization of viral recombinants. (A) EBV-wt, D123, and D123 Rev restriction enzyme analysis. A schematic map of the EBV-wt
genome segment encompassing the BHRF1 region with cleavage sites for AclI and HindIII and the expected fragment sizes are shown on the top
panel. The recombinant viral genomes isolated either from E.coli cells or rescued from stably transfected HEK293 cells were cleaved with AclI (left) or
HindIII (right). While the exchange of miR-BHRF1-2 and miR-BHRF1-3 against a frt-site introduced a HindIII restriction site, the mutation of miR-BHRF1-
1 introduced an AclI restriction site. The fragment size predictions for each enzyme are given and the resulting fragment changes observed after
restriction analysis are indicated with arrows (lower panel). H3: HindIII; M: molecular weight marker; frt: flp recombinase target site. (B) Viral genome
DNA equivalents (geq) per ml of supernatant were quantified by qPCR amplification of the viral BALF5 gene. Concentration of infectious particles per
ml of supernatant were calculated by counting gfp-positive Raji units (gru). Mean values of 3 different supernatants are presented.
doi:10.1371/journal.ppat.1001294.g002
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assays were carried out at low B cell concentration (10
2/well) with an MOI of 1 gru per B cell. An average of the results of three independent infection
experiments is presented. (B) Growth curve of EBV-infected B cells in the first weeks post-infection. Mean values of three independent B cell infection
experiments are shown. (C) Cell cycle analysis of BrdU-7AAD-stained LCLs generated with D123, D123 Rev, and EBV-wt viruses. The percentage of
cells present in S or G2/M phase of the cell cycle is given. (D) BHRF1 miRNA expression profile. Shown are RT-PCR amplification products from one LCL
set generated with D123, D123 Rev, or EBV-wt viruses using primers specific for miR-BHRF1-1, miR-BHRF1-2, and miR-BHRF1-3. Amplification of
RNU48 served as an internal reference, and BJAB cells were used as a miRNA negative control. (E) Three unrelated B cell samples (a, b, and c) were
infected with D123, D123 Rev, or EBV-wt viruses and BHRF1 miRNA expression was evaluated at day 11 p.i. Results are presented relative to the values
obtained with one LCL (a) exposed to EBV-wt. The mean value of three independent analyses are shown.
doi:10.1371/journal.ppat.1001294.g003
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retain a high latent gene level of transcription and
translation over time
The latent viral proteins have been recognized as the principal
mediators of EBV’s transforming properties. It was therefore
important to assess latent gene expression in B cells infected with
the EBV D123 mutant. To this aim, we carried out RT-qPCR
analysis of the viral latent transcripts produced from the Wp and
Cp promoters in transformed Bcell lines at 5, 11, 25, 36, and 73
days after infection (Fig. 4A). At day 5, the level of transcription
from the Cp and Wp promoters was very similar in cells infected
with D123 and in wild type controls. However, from day 11 on,
the activity of the Wp promoter, and of the Cp promoter gradually
increased in B cells transformed with the triple mutant relative to
their control counterparts (Fig. 4A). Rather than an absolute
increase of Wp transcriptional activity in D123-positive B cell lines,
the observed differences could be ascribed to a stronger down-
regulation of Wp in the controls (Fig. 4B).
These results suggested that the BHRF1 miRNA cluster,
directly or indirectly, negatively regulates the expression of Wp/
Cp-driven transcripts. Alternatively, these results could be
accounted for by selection of a minor population of B cells that
happens to express very high levels of EBV latent genes,
provided that such an overexpression confers a growth
advantage in LCLs infected by EBV D123 mutant. To test this
hypothesis, we performed clonality studies of the LCLs at the
different time points used in transcriptional studies reported
above (Fig. 4C). To this aim, immunoglobulin heavy chain (IgH)
genes were amplified by PCR using degenerated primers that
bind to a large number of IgH variable gene families [17]. Whilst
an IgH PCR performed on monoclonal B cell populations will
reveal a unique band, it will yield a smear that ranges between
approximately 330 and 350 bp if applied to a polyclonal B cell
population as the length of different IgH family members slightly
differs [17]. IgH PCR performed on LCLs generated with D123
or with wild type virus controls displayed a polyclonal pattern at
Figure 4. Latent promoter usage and clonality studies of transformed B cells. (A) Wp and Cp-initiated transcripts were monitored by RT-
qPCR in B cells transformed with D123, D123 Rev, or EBV-wt virus at multiple time points post-infection. Results obtained at a given time point are
grouped and presented relative to EBV-wt at the same time point. Results represent mean values obtained from three independent analyses. (B) The
same data as in (A) presented relative to the value observed in B cells infected by EBV-wt five days after infection. This illustrates Wp and Cp activities
over time in B cells infected by D123 mutant or wild type counterparts. (C) Clonality of LCLs generated with D123, D123 Rev, or EBV-wt virus was
determined by a PCR-based assay using primers specific to the IgVH sequences. Cell populations were analyzed at different time points post-
infection. Akata is a monoclonal B cell line; non-infected primary B cells (day 0) are polyclonal in nature. NTC: no template control.
doi:10.1371/journal.ppat.1001294.g004
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From day 36 on, discrete bands become visible against a
polyclonal background, and at day 73 all three cell lines
contained multiple dominant discrete clones, ie they became
oligoclonal (Fig. 4C). From these results, we infer that early
selection of dominant clones does not take place in the LCL
infected by the EBV D123 mutant.
We then used RT-qPCR and western blots to gauge EBV latent
gene expression. The results of one out of four experiments are
shown in Figure 5. This set of experiments demonstrated that B
cells generated with the D123 virus express all tested latent genes
with some expressed at higher levels than in the controls at day 11
post-infection (Fig. 5A). Similar assays conducted at day 36 post-
infection confirmed this trend; all latent genes were expressed at
Figure 5. Latent gene expression profiles of B cells transformed byD123 virus. (A) and (B) EBV latent gene transcription and translation in
LCLs transformed by D123, D123 Rev, or EBV-wt virus were examined by RT-qPCR (right panel) and western blot analysis (left panel) at day 11 (A) and
day 36 (B) post-infection (dpi). Results from one representative experiment are presented. Intensity of western blot signals was measured using
ImageJ software. Given below each western blot is the ratio between the intensity of the observed signal and the wt signal (wt set as 1). (C) BHRF1
gene transcription in LCLs transformed by D123, D123 Rev, or EBV-wt virus as measured by RT-qPCR. Data are means from three independent
infection experiments.
doi:10.1371/journal.ppat.1001294.g005
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protein level (Fig. 5B). This difference was particularly dramatic in
the case of the EBNA-LP protein, which was five times more
abundant in LCLs generated with D123 than in controls, but was
also visible for EBNA1, EBNA2, EBNA3A, EBNA3B, and
EBNA3C. LMP1 and LMP2-specific transcripts were also more
abundant in LCLs infected by the triple mutant. Western blot
analysis detected a marginal increase in LMP1 protein production
in the same cells. Recent recognition that the BHRF1 protein is
important for B cell transformation prompted us to assess
expression of this gene [18]. Lymphoblastoid cell lines infected
with wt, D123, or D123 Rev viruses evinced similar levels of
BHRF1 transcripts (Fig. 5C).
Discussion
Since their initial discovery in the EBV genome, miRNAs have
been found in all investigated herpesviruses [19,20]. Although
some of these miRNAs moderate the expression of virus
replication proteins, e.g. miR BART2 and the EBV viral
polymerase BART5, miR-H2, and the ICP0 transactivator, many
have been found to regulate virus-cell interactions [21,22].
Maintenance of latency appears to be a recurrent theme across
herpes viruses [20,23]. Examples are provided by HSV1 miR-M2-
3p that inhibits translation of ICP0, a key transactivator that
initiates virus lytic replication [22]. More recently, a cluster of 12
pre-miRNAs from the KHSV genome has been implicated in the
repression of lytic replication through its ability to down-regulate
IkBa [24]. Facilitation of immune evasion appears to be another
crucial function served by several virus miRNAs [20]. Indeed,
miR-UL112-1 from HCMV curbs synthesis of the NK cellular cell
surface receptor MICB and EBV miR-BHRF1-3 prevents
production of the putative T cell chemoattractant CXCL11
[25,26]. In the present paper, we expand the spectrum of functions
served by viral miRNAs during virus latency. We provide clear
evidence that the BHRF1 miRNA cluster substantially enhances
EBV’s transforming potential. In its absence, B cells infected with
the same functional MOI grew more slowly and could not
efficiently form colonies at low concentration. Although we usually
see EBV-mediated transformation as the molecular mechanism
that underlies EBV’s oncogenic properties, it is also activated
during primary infection, presumably to expand the size of the
Bcell reservoir. Our observations suggest that in the absence of the
BHRF1 miRNA cluster, expansion of this compartment would be
substantially reduced.
Importantly, the D123 defective phenotype could not be
ascribed to a down-regulation of latent protein expression. This
family of proteins has been found to activate several signal
transduction pathways that include the Notch, NFkB, Jun, AP1,
and JAK-Stat pathways and is therefore thought to be the
principal effector of B cell transformation [14]. Although the
level of latent transcription was nearly identical in B cells
infected with D123 or in controls at day 5 post-infection, a
divergence between both virus types became discernible after 11
days and became obvious after 3 weeks in culture. While B cells
transformed with wild type viruses progressively but efficiently
down-regulated Wp transcription starting at five days after
infection, this process was much less efficient in cells trans-
formed with D123 virus. In this respect, It is interesting to note
that the kinetics of expression of the BHRF1 miRNA cluster and
of Wp transcripts are exactly opposite; while miR-BHRF1-3
expression starts at day one and linearly increases until day 8,
Wp transcripts are maximal at day 1 and sharply decrease until
day 8 after which they more slowly reach a minimum plateau at
day 20 [27,28]. However, B cells infected by the D123 virus
mutant also exhibited an increase in the abundance of Cp-
initiated transcripts as soon as this promoter became dominant,
three weeks after infection. Therefore, the deletion of the
BHRF1 miRNA cluster prevents repression of the Wp
transcripts and enhances expression of the Cp promoter.
This could suggest that the latent transcripts, from which the
latent genes originate, are direct targets of the miRNA BHRF1
cluster. However, the high amplitude of the effects caused by the
absence of the BHRF1 miRNAs is not consonant with those
usually observed with viral or cellular miRNAs, even if we
hypothesize a synergistic effect of the three miRNAs. Rather, they
suggest that the BHRF1 cluster may target one or more cellular
transactivators, many of which (BSAP/pax5, RFX1, YY1, MIBP1,
CREB, ATF1) have been shown to regulate expression of the Wp/
Cp promoters [14]. Using the photoactivatable ribonucleoside-
enhanced crosslinking and immunoprecipitation (PAR-CLIP)
technique recently described by the Tuschl laboratory [29], we
have comprehensively identified mRNAs bound by all of the viral
and cellular miRNAs expressed in LCLs (R. Skalsky and B.
Cullen, manuscript in preparation). Using this technology, we
have identified ,300 mRNA targets for the EBV BHRF1
miRNAs. Although strong binding sites for cellular miRNAs on
the viral LMP1 and BHRF1 mRNAs were readily detected, none
of the latent EBV mRNAs were bound by any of the BHRF1
miRNAs. We therefore conclude that the observed effect of these
viral miRNAs on EBV latent gene expression is indirect.
The enhanced latent transcription observed in B cells infected
with D123 virus correlated with an increased production of latent
proteins relative to wild type controls. This effect was most visible
for EBNA-LP, but EBNA1, EBNA2, EBNA3A, EBNA3B,
EBNA3C, and LMP2A were all more strongly expressed in B
cells infected with the triple miRNA mutant. Therefore, the total
amount of viral antigens present in B cells transformed by D123 is
substantially higher than seen in wild type controls. Latent
proteins, and in particular EBNA1, EBNA3A, and EBNA3C,
have been shown to elicit a strong CD8+ T-cell response directed
against EBV-infected cells. We infer from these data that the
BHRF1 cluster reduces the antigenic load present in B cells and
could therefore facilitate viral immune evasion [2] and thus
persistence, a common trait of herpes viruses [20].
Is there a causal relationship between the relative excess of
latent proteins observed in B cells transformed by D123 and the
reduced growth rate? An excess of LMP1 has been reported to
exert toxic effects on infected B cells [3], but the expression level
obtained from the expression plasmid used in this work appears
much higher than observed in D123-transformed LCLs. We
therefore favor the view that the excess of latent genes cannot fully
explain the D123 phenotype and that the BHRF1 cluster also acts
independently of the viral latent genes, probably by targeting
cellular genes involved in cell growth control.
Our data clearly document that the BHRF1 miRNA cluster
serves a central function in EBV biology as it enhances the virus’
ability to dysregulate B cell growth. Thus, the miRNA cluster
expands the size of EBV’s reservoir and enhances its oncogenic
property. Therefore, it represents a new potential therapeutic
target for the treatment of EBV-associated diseases.
Materials and Methods
Primary cells and cell lines
HEK293 cells are neuro-endocrine cells obtained by transfor-
mation of embryonic epithelial kidney cells with adenovirus
[30,31]. Raji and Akata are EBV-positive Burkitt’s lymphoma cell
EBV microRNAs and B Cell Transformation
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34]. WI38 are primary human lung embryonic fibroblasts [35]. All
cell lines were grown in RPMI 1640 medium supplemented with
10% fetal calf serum (FCS; Biochrom).
Plasmids
We introduced mutations in miR-BHRF1-1 (B95.8 co-ordinates
53762-53782; accession number V01555.2) by overlap PCR using
mutated primers (TAACCTGATCAGCCCC changed into
TAACGTTGCAAGCCCC). This gave rise to a 1.8 kb fragment
(B95.8 coordinates 52807-54651) that encompasses a BHRF1-1
miRNA with a mutated seed region. Furthermore, the introduced
mutation creates an AclI restriction site that allows distinction
between the wild type and the mutated sequences (see also Fig. 1).
The 1.8 kb PCR fragment was cloned into a plasmid (B269) that
consists of an arabinose-inducible temperature sensitive bacterial
origin of replication, the ampicillin (amp) resistance gene, RecA
and the LacZ operon to generate a shuttle vector (B396) for
chromosomal building. A 2.9 kb BspT1/SalI fragment (B95.8
coordinates 53222-56081) was cloned into the vector B269 to
generate the shuttle vector for construction of the D 23 revertant
(B 430).
Construction of viral mutant and revertant
The wild-type EBV B95.8 strain cloned onto a prokaryotic F-
plasmid, which carries the chloramphenicol (cam) resistance gene,
the gene for the green fluorescent protein (GFP), and the
hygromycin (hyg) resistance gene (p2089) [36], was used to
generate the BHRF1 miRNA mutant. Deletion of miR-BHRF1-1
was performed by chromosomal building as described [16] using
B396 as targeting vector. This involved initial building of a
cointegrate between the shuttle vector that contains the mutated
version of the mature miR-BHRF1-1 and the wild type EBV
genome. This co-integrate that as a result of recombination carries
both mutated and wild type miR-BHRF1-1 was then resolved to
eliminate the wild type copy of the miRNA. Subsequently, a triple
mutant lacking all three BHRF1 miRNAs was obtained by
exchanging the viral DNA fragment that contains both mature
miR-BHRF1-2 and miR-BHRF1-3 and the sequence between
them (B95.8 co-ordinates 55176-55279) against the kanamycin
resistance gene flanked by flp-recombination sites as described
[16]. The kanamycin resistance cassette from pCP15 was ampli-
fied using primers 682 CTTTTAAATTCTGTTGCAGCAGA-
TAGCTGATACCCAATGTAACAGCTATGACCATGATTA-
CGCC and 683 ATTTTAACGAAGAGCGTGAAGCACCGC-
TTGCAAATTACGTCCAGTCACGACGTTGTAAAACGAC.
The kanamycin cassette was excised from recombined clones by
transient transformation of the Flp recombinase cloned onto a
temperature-sensitive plasmid (pCP20). A revertant clone for D123
was constructed by chromosomal building using the shuttle vector
described above.
Stable clone selection and plasmid rescue in E.coli
Recombinant EBV plasmids were transfected into HEK293
cells by lipofection (Metafectene, Biontex) and selected for
hygromycin resistance (100 mg/ml). Recombinant EBV genomes
were purified from GFP-positive hygromycin-resistant cell clones
as described [37] and electroporated into E. coli DH10B cells (1200
V, 25 mF, 200 V). The genetic integrity of the mutant or revertant
EBV genomes stably introduced in HEK293 cell clones was
assessed by restriction enzyme analysis and DNA sequencing of
the BHRF1 gene region. The mutant producer cell clones were
designated as 293/D123 and the revertant producer clones thereof
as 293/D123 Rev.
Virus induction and titer quantification
All described producer cell lines clones were lytically induced by
transfection of a BZLF1 expression plasmid together with a
BALF4 expression plasmid (3 mg each/6-well plate). Medium was
changed at day 1 post-infection (p.i.), virus supernatant harvested
at day 4 p.i., filtered through a 0.45 mm filter, and stored in
aliquots at 280uC. Viral genome equivalents (geq) were deter-
mined by quantitative real-time PCR using EBV BALF5-specific
primers and probe as described [38]. Infectious titers were
determined by infecting 10
4 Raji B cells with increasing 5-fold
dilutions of supernatants. Three days after infection, gfp-positive
cells were counted using a fluorescent microscope.
Infection of primary B lymphocytes
Primary B cells were freshly isolated from adult human blood
buffy coats by density gradient centrifugation followed by positive
selection usingM-450CD19 Dynabeads(Dynal). To quantify EBV-
mediated B cell transformation rates, freshly isolated primary B cells
were exposed to infectious supernatants at a MOI of 1 infectious
particle (gru) per B cell overnight at 37uC and then seeded at a
concentration of 100 cells per well in 96-U-well plates coated with
lethally irradiated WI38 feeder cells. The number of wells with
proliferating cells was determined 8 weeks post-infection. Infection
experiments were also carried out at high B cell concentration;
2x10e6 B cells were exposed to infectious supernatant at an MOI of
1 infectious particle per cell and were harvested for RNA and
protein extraction at different time points post-infection.
Stem-loop real-time PCR
BHRF1 miRNAs extracted from lymphoblastoid cell clones were
reverse transcribed using specific stem-loop primers and TaqMan
miRNA reverse Transcription Kit (Applied Biosystems) as described
elsewhere [28,39]. In brief, 110 ng of total RNA isolated with a
miRNA extraction kit (Qiagen) was reverse transcribed as recom-
mended by the manufacturer. The sequences of stem-loop primer,
primer and probes and the qPCR conditions were identical to those
described elsewhere [28]. Reverse transcription and amplification of
cellular snoRNA RNU48 was performed in parallel to normalize for
cDNA recovery (Assay ID 001006; Applied Biosystems) as
recommended by the manufacturer. Real-time PCR was performed
on an ABI 7300 Sequence Detection System (Applied Biosystems).
All reactions were run in duplicates. An aliquot of the PCR reaction
was taken after 30 cycles, products were loaded onto a 8%
polyacrylamide gel and visualized by ethidium bromide staining.
Western blot analysis
Cells were resuspended in PBS and lysed by sonication. 30 mgo f
proteins were denatured in Laemmli buffer for 5 minutes at 95uC,
separated on a 10% or 7.5% SDS-polyacrylamide gel and
electroblotted onto a Hybond ECL membrane (Amersham). After
preincubation for 30 min in 5% milk powder in PBS, blots were
incubated with primary antibodies EBNA1 (IH4), EBNA2 (PE2),
LMP1 (S12), EBNA-LP (JF186), EBNA3A (ExAlpha), EBNA3B
(ExAlpha), EBNA3C (A10), or actin (clone ACTN05; Dianova) for
1 h at room temperature. After several washings in 0.1% Tween in
PBS, blots were incubated for 1 h with secondary antibodies coupled
with horseradish peroxidase. Antibody binding was revealed using an
ECL detection reagent (Perkin Elmer). Densitometric analyses of
immunoblots were performed using ImageJ software.
Real-time PCR of EBV latent genes
400 ng aliquots of RNA isolated from infected B cells
(miRNeasy kit, Qiagen) was reverse transcribed with AMV-RT
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and specific for GAPDH as described [18,40]. Quantitative PCR
using primers specific for Cp, Wp, LMP1, LMP2A, EBNA2, and
YUK-spliced EBNA1 transcripts were performed as described
[40]. PCR and data analysis was carried out using the universal
thermal cycling protocol on an Applied Biosystem 7300 real-time
PCR System. All samples were run in duplicates, together with
primers for the amplification of the human GAPDH gene in
combination with a VIC-labeled probe (Applied Biosystems) to
normalize for variations in cDNA recovery.
Cell cycle analysis
Cell cycle parameters of exponentially growing lymphoblastoid
cell lines phase were monitored by exposing 1610
6cells for 30
minutes to BrdU (10 mM final concentration) (BrdU flow kit, BD
Biosciences Pharmingen, San Diego, USA). The degree of
incorporation was determined by immunostaining with an APC-
coupled antibody directed against BrdU. DNA content was
assessed by staining cells with the DNA intercalating dye 7-
AAD. Analysis of fluorescence with a two laser FACScalibur flow
cytometer allows identification of cells that have entered the S
phase (BrdU positive), the G2/M phase (BrdU negative, double
DNA content) or the G0/G1 phase (BrdU negative, double DNA
content).
PCR amplification of variable IgH sequences
DNA was extracted from 1 to 3610
6 cells using a DNeasy
Tissue kit (Qiagen). IgH variable (IgVH) sequences spanning FR1,
CDR1, FR2, CDR2, FR3, and CDR3 were PCR-amplified using
a single consensus forward primer FR1c:59AGGTGCAGC-
TGSWGSAGTCDGG 39 and a mixture of JH family-specific
reverse primers JH1/2/4/5 59-ACCTGAGGAGACGGTGAC-
CAGGGT-39, JH3 59- TACCTGAAGAGACGGTGACCAT-
TGT-39 and JH6 59- ACCTGAGGAGACGGTGACCGT-
GGT-39 described previously [17]. PCR amplification was
performed in a reaction containing 1 mg heat denatured (10 min
at 94uC) genomic DNA, 0.8 mM FR1c primer, 0.26 mM of each
JH primer, 200 mM of each dNTP, 1.0 mM MgCl2, and 2.5 U
Expand High Fidelity thermostable DNA polymerase (Roche).
The first PCR cycle consisted of a denaturing step at 94uC for
2 min, followed by 30 cycles at 94uC for 30 s, at 61uC for 60 s,
and at 72uC for 60 s (10 min in the last cycle). PCR products were
then separated by electrophoresis on a 6% polyacrylamide gel, and
bands corresponding to the 330–350 bp IgVH products visualized
by ethidiumbromide staining.
Supporting Information
Figure S1 Sequence of the BHRF1 region in wt and D 123
mutant. (A) EBV-wt sequence. Location of the BHRF1 intron
(blue lettering), the BHRF1 open reading frame (green lettering)
and the BHRF1 TATA box, the translation initiation site and poly
A site (boxes) are indicated. The three BHRF1 pre-miRNAs are
shown in red, the mature miRNAs in orange. (B) D 123 sequence.
Transcripts are indicated in the same colors as described above.
The miR-BHRF1-1 sequence was mutated at 5 positions (black
lower case lettering). The region spanning the mature BHRF1-2
and BHRF1-3 miRNAs were replaced by a frt recombination site
(boxed) and additional flanking sequences from the targeting
vector. Corresponding EBV coordinates refer to the EBV B95.8
stain (accession number V01555.2).
Found at: doi:10.1371/journal.ppat.1001294.s001 (2.62 MB TIF)
Figure S2 Electropherogram of sequenced miRNA regions in
the D 123 mutant and D 123 revertant. (A) Shown is the sequenced
lower strand spanning miR-BHRF1-1 (underlined) from B95.8
coordinates 53823 to 53701 (accession number V01555.2). The
seed region of BHRF1-1 is boxed, the introduced mutations in the
D 123 mutant (upper panel) are highlighted by arrows. The lower
panel shows that the same DNA region in the D 123 revertant is
identical to the wt miR-BHRF1-1 sequence. (B) DNA fragment
spanning the BHRF1-2 and BHRF1-3 miRNAs. Upper panel: In
the D 123 mutant, the BHRF1-2 and BHRF1-3 miRNAs are
replaced by sequences from the kanamycin targeting plasmid
(underlined in orange) including one frt site (boxed). EBV-specific
sequences are underlined in black. Lower panel: Sequence
spanning miR-BHRF1-2 and miR-BHRF1-3 (underlined) in the
D 123 revertant shows perfect homology to EBV-wt sequences.
B95.8 coordinates are indicated.
Found at: doi:10.1371/journal.ppat.1001294.s002 (2.76 MB TIF)
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